Feb. 26 at 1:32 AM
$ABCL I am following the company since its IPO and know it in and out. I have been warning many times tha
$5-6 was too high for the stage of the company. But here at
$3,2 with a huge war chest of
$700 Million in current assets and a broad pipeline of 20+ own discoveries plus another 50 partner programs that are most likely getting into clinical trials chances of ABCL hitting the jackpot is extremely high for a biotech. They have enough cash until they hit that one drug that gives them enough cash to spit out more and more blockbusters. They have the discovery engine (that they are not willing to share anymore), they have the manufacturing capabilities, they have a top management. Note also how fast ABCL 635 progressed from discovery to now phase 2 readout in Q3 2026! A good readout and company revalues to the upside. Second best buy at this price after
$GLSI in the market right now. At this price it is free money!
